Literature DB >> 19725487

Treatment options for acne rosacea.

Constance Goldgar1, David J Keahey, John Houchins.   

Abstract

Rosacea is a common chronic, and sometimes progressive, dermatosis. It is characterized, alone or in combination, by central facial erythema,symmetric flushing, stinging sensation, inflammatory lesions (papules and pustules), telangiectasias, and phymatous changes (tissue hyperplasia and nodules). Rosacea can occur in adults of any ethnicity,and adversely affects patients' quality of life. The condition can be effectively controlled with therapy tailored to the specific subtype of rosacea that is affecting the patient. Topical metronidazole, sulfacetamide/sulfur, and azelaic acid are generally effective for patients with mild rosacea. For moderate papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Treatment with a topical agent, such as metronidazole, may help maintain remission. Patients with ocular involvement may benefit from long-term oral antibiotics and metronidazole gel. Referral to a subspecialist is necessary for patients who have ocular rosacea with ophthalmic complications, severe or recalcitrant rosacea, or phymatous changes.

Entities:  

Mesh:

Year:  2009        PMID: 19725487

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  7 in total

1.  Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.

Authors:  Todd Williamson; Rajesh Kamalakar; Augustina Ogbonnaya; Erin A Zagadailov; Michael Eaddy; Charlie Kreilick
Journal:  Am Health Drug Benefits       Date:  2017-05

2.  Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.

Authors:  Linda Stein Gold; James Q Del Rosso; Leon Kircik; Neal D Bhatia; Deirdre Hooper; Walter Nahm; Iain Stuart
Journal:  J Clin Aesthet Dermatol       Date:  2020-11-01

3.  Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.

Authors:  Terry M Jones; Iain Stuart
Journal:  J Clin Aesthet Dermatol       Date:  2021-03-01

4.  Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life.

Authors:  Tu T Huynh
Journal:  Am Health Drug Benefits       Date:  2013-07

5.  Preliminary open-label clinical evaluation of the soothing and reepithelialization properties of a novel topical formulation for rosacea.

Authors:  Adele Sparavigna; Beatrice Tenconi; Ileana De Ponti
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-10-24

6.  Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.

Authors:  M Schaller; L M C Almeida; A Bewley; B Cribier; J Del Rosso; N C Dlova; R L Gallo; R D Granstein; G Kautz; M J Mannis; G Micali; H H Oon; M Rajagopalan; M Steinhoff; E Tanghetti; D Thiboutot; P Troielli; G Webster; M Zierhut; E J van Zuuren; J Tan
Journal:  Br J Dermatol       Date:  2019-10-16       Impact factor: 9.302

7.  The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis.

Authors:  Kashif Siddiqui; Linda Stein Gold; Japinder Gill
Journal:  Springerplus       Date:  2016-07-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.